The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Cited by
Sorted by citations
Items 901–1,000 of 1,029
Zhang, L., Cheng, Q., Li, C., Zeng, X., & Zhang, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120029 · Cited by 92
Picciotto, S., Barone, M. E., Fierli, D., Aranyos, A., Adamo, G., Božič, D., Romancino, D. P., Stanly, C., Parkes, R., Morsbach, S., et al. (2021) · Biomaterials Science · doi:10.1039/d0bm01696a · Cited by 93
Use of Protamine in Nanopharmaceuticals—A Review
Ruseska, I., Fresacher, K., Petschacher, C., & Zimmer, A. (2021) · Nanomaterials · doi:10.3390/nano11061508 · Cited by 93
Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery
Olshefsky, A., Richardson, C., Pun, S. H., & King, N. P. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00030 · Cited by 94
Ornelas, C., & Astruc, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082044 · Cited by 101
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
Bian, X., Zhou, L., Luo, Z., Liu, G., Hang, Z., Li, H., Li, F., & Wen, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c11858 · Cited by 101
Zhang, F., Magruder, J. T., Lin, Y.-A., Crawford, T. C., Grimm, J. C., Sciortino, C. M., Wilson, M. A., Blue, M. E., Kannan, S., Johnston, M. V., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.032 · Cited by 92
“For these nanoparticles, particles size plays the primary role in determining the mode of clearance [22].”
Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
“However, a significant barrier for using nanoparticles is the fact that despite being able extravasate and persist due to EPR, only a very small percentage (less than 1%) of injected nanoparticles are actually able to traffic and be delivered to their intended destination (130, 131).”
BackgroundMekuria, S. L., Debele, T. A., & Tsai, H. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b14075 · Cited by 91
Liu, X. H., Shao, W., Zheng, Y.-J., Yao, C., Peng, L., Zhang, D., Hu, X., & Wang, L. (2017) · Chemical Communications · doi:10.1039/c7cc04932c · Cited by 91
Licciardello, N., Hunoldt, S., Bergmann, R., Singh, G., Mamat, C., Faramus, A., Ddungu, J. L. Z., Silvestrini, S., Maggini, M., Cola, L. D., et al. (2018) · Nanoscale · doi:10.1039/c8nr01063c · Cited by 95
Magnetic nanoparticles based cancer therapy: current status and applications
Zhang, H., Liu, X., Zhang, Y. F., Gao, F., Li, G., He, Y., Peng, M., & Fan, H. M. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9271-1 · Cited by 92
Bioengineered Macrophages Can Responsively Transform into Nanovesicles To Target Lung Metastasis
Cao, H., Wang, H., He, X., Tan, T., Hu, H., Wang, Z., Wang, J., Li, J., Zhang, Z., & Li, Y. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01236 · Cited by 91
Piloni, A., Wong, C. K., Chen, F., Lord, M. S., Walther, A., & Stenzel, M. H. (2019) · Nanoscale · doi:10.1039/c9nr06835j · Cited by 91
Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy
Nguyen, A., Ramesh, A., Kumar, S., Nandi, D., Brouillard, A., Wells, A. C., Pobezinsky, L. A., Osborne, B. A., & Kulkarni, A. A. (2020) · Science Advances · doi:10.1126/sciadv.abc2777 · Cited by 91
“Previous studies have shown that nanoparticles of size ~200 nm can accumulate in solid tumors while escaping liver and spleen filtration (30).”
Controlled drug delivery systems in eradicating bacterial biofilm-associated infections
Liu, Y., Li, Y., & Shi, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.038 · Cited by 94
Mixed Zn–Ni spinel ferrites: Structure, magnetic hyperthermia and photocatalytic properties
Manohar, A., Krishnamoorthi, C., & Kim, K. H. (2020) · Ceramics International · doi:10.1016/j.ceramint.2020.11.056 · Cited by 91
Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics
Jahan, S., Karim, M. E., & Chowdhury, E. H. (2021) · Biomedicines · doi:10.3390/biomedicines9020114 · Cited by 92
Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies
Wang, Y., Wang, J., Zhu, D., Wang, Y., Qing, G., Zhang, Y., Liu, X., & Liang, X. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.007 · Cited by 93
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91
“Some nanoparticles designs implement surface modifications such as peptides, PEG, or cell membrane coatings to reduce these interactions with phagocytic cells [18].”
BackgroundNano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy
Guo, J., Zou, Y., & Huang, L. (2023) · Small Methods · doi:10.1002/smtd.202201307 · Cited by 91
Deformable nanocarriers for enhanced drug delivery and cancer therapy
Cao, Z., Liu, J., & Yang, X. (2024) · Exploration · doi:10.1002/exp.20230037 · Cited by 91
Drug delivery using gold nanoparticles
Dykman, L. A., Khlebtsov, B. N., & Khlebtsov, N. G. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115481 · Cited by 101
Liu, X., Jia, K., Wang, Y., Shao, W., Yao, C., Peng, L., Zhang, D., Hu, X., & Wang, L. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b00643 · Cited by 90
The Potential of Biomimetic Nanoparticles for Tumor-Targeted Drug Delivery
Li, B., Wang, F., Gui, L., He, Q. G., Yao, Y., & Chen, H. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0017 · Cited by 92
“Immune cell membrane The cumulative accumulation of cancer damage is mainly hampered by several biological barriers, such as mononuclear phagocytic systems, tumor extracellular matrix, tumor-associated vasculature and cell membranes [43,131,148].”
BackgroundTumor targeting DVDMS-nanoliposomes for an enhanced sonodynamic therapy of gliomas
Sun, Y. L., Wang, H., Wang, P., Zhang, K., Geng, X., Liu, Q., & Wang, X. (2018) · Biomaterials Science · doi:10.1039/c8bm01187g · Cited by 90
Zhang, J., Lin, Y., Zhou, H., He, H., Ma, J., Luo, M., Zhang, Z., & Pang, D. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900341 · Cited by 90
Virus-Sized Gold Nanorods: Plasmonic Particles for Biology
Murphy, C. J., Chang, H.-H., Falagan-Lotsch, P., Gole, M. T., Hofmann, D., Hoang, K. N. L., McClain, S. M., Meyer, S. M., Turner, J. G., Unnikrishnan, M., et al. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00288 · Cited by 90
Ghosh, A., Xu, W., Gupta, N., & Gracias, D. H. (2020) · Nano Today · doi:10.1016/j.nantod.2019.100836 · Cited by 90
Wang, G., Zhang, C., Jiang, Y., Song, Y. H., Chen, J., Sun, Y., Li, Q., Zhou, Z., Shen, Y., & Huang, P. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202102786 · Cited by 91
Extracellular Vesicle-Based Hybrid Systems for Advanced Drug Delivery
Rodríguez, D. A., & Vader, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020267 · Cited by 95
Al-Jipouri, A., Almurisi, S. H., AL-Japairai, K. A. S., Bakar, L. M., & Doolaanea, A. A. (2023) · Polymers · doi:10.3390/polym15020318 · Cited by 97
Evolution of nanomedicine formulations for targeted delivery and controlled release
Puri, S., Mazza, M., Roy, G., England, R., Zhou, L., Nourian, S., & Subramony, J. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114962 · Cited by 94
Impact of protein coronas on nanoparticle interactions with tissues and targeted delivery
Chou, W., & Lin, Z. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103046 · Cited by 93
IR780-loaded TPGS-TOS micelles for breast cancer photodynamic therapy
Pais‐Silva, C., de Melo‐Diogo, D., & Correia, I. J. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.01.002 · Cited by 88
Cyanine based Nanoprobes for Cancer Theranostics
Bhattarai, P., & Dai, Z. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700262 · Cited by 89
Jo, S. D., Nam, G., Kwak, G., Yang, Y., & Kwon, I. C. (2017) · Nano Today · doi:10.1016/j.nantod.2017.10.008 · Cited by 89
Hu, H., Xiao, C., Wu, H., Li, Y., Zhou, Q., Tang, Y., Yu, C., Yang, X., & Li, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b14796 · Cited by 87
Nanomedicine, an emerging therapeutic strategy for oral cancer therapy
Marcazzan, S., Varoni, E. M., Blanco, E., Lodi, G., & Mauro Ferrari, B. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.11.014 · Cited by 89
Self-citationMarin, R., Skripka, A., Besteiro, L. V., Benayas, A., Wang, Z., Govorov, A. O., Canton, P., & Vetrone, F. (2018) · Small · doi:10.1002/smll.201803282 · Cited by 89
Biomaterials as vectors for the delivery of CRISPR–Cas9
Eoh, J. H., & Gu, L. (2019) · Biomaterials Science · doi:10.1039/c8bm01310a · Cited by 92
Taha, M. S., Padmakumar, S., Singh, A., & Amiji, M. M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00744-1 · Cited by 93
“Size for example is the defining aspect of a nanoparticle DP, which influences its biological distribution, clearance pathway, drug release profile, and interaction with the immunological components of the body [173].”
BackgroundXu, F., Zhu, J., Lin, L., Zhang, C., Sun, W., Fan, Y., Yin, F., van Hest, J. C. M., Wang, H., Du, L., et al. (2020) · Theranostics · doi:10.7150/thno.43402 · Cited by 89
“Notably, only a small part of NGs was distributed within the spleen and lung, indicating that the NGs possessed a good size distribution and no obvious particle aggregation occurred during the circulation [41].”
Inorganic Porous Nanoparticles for Drug Delivery in Antitumoral Therapy
Parra‐Nieto, J., del Cid, M. A. G., de Cárcer, I. A., & Baeza, A. (2020) · Biotechnology Journal · doi:10.1002/biot.202000150 · Cited by 91
Recent Advances in Nanoencapsulation of Phytochemicals to Combat Obesity and Its Comorbidities
Göktaş, Z., Zu, Y., Abbasi, M., Galyean, S., Wu, D., Fan, Z., & Wang, S. F. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c00131 · Cited by 95
Nanoparticles in the Biological Context: Surface Morphology and Protein Corona Formation
Richtering, W. H., Alberg, I., & Zentel, R. (2020) · Small · doi:10.1002/smll.202002162 · Cited by 90
DNA origami nanostructures for controlled therapeutic drug delivery
Weiden, J., & Bastings, M. M. C. (2020) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2020.101411 · Cited by 91
Sonoporation: Past, Present, and Future
Rich, J. T., Tian, Z., & Huang, T. J. (2021) · Advanced Materials Technologies · doi:10.1002/admt.202100885 · Cited by 92
Microfluidic nanomaterials: From synthesis to biomedical applications
Illath, K., Kar, S., Gupta, P., Shinde, A. S., Wankhar, S., Tseng, F., Lim, K., Nagai, M., & Santra, T. S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121247 · Cited by 89
Allawadhi, P., Singh, V., Govindaraj, K., Khurana, I., Sarode, L. P., Navik, U., Banothu, A. K., Weiskirchen, R., Bharani, K. K., & Khurana, A. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118923 · Cited by 90
“Researchers have successfully generated nano-carriers that can specifically respond to biological or physical stimuli are called as smart or intelligent delivery system [128].”
BackgroundAcoustofluidics for simultaneous nanoparticle-based drug loading and exosome encapsulation
Wang, Z., Rich, J. T., Hao, N., Gu, Y., Chen, C., Yang, S., Zhang, P., & Huang, T. J. (2022) · Microsystems & Nanoengineering · doi:10.1038/s41378-022-00374-2 · Cited by 92
Quality by Design Approach in Liposomal Formulations: Robust Product Development
Alshaer, W., Nsairat, H., Lafi, Z., Hourani, O. M., Al-Kadash, A., Esawi, E., & Alkilany, A. M. (2022) · Molecules · doi:10.3390/molecules28010010 · Cited by 100
“For better biodistribution, the ideal nanocarrier particle size should be in the range of 10 to 100 nm to avoid kidney elimination, escape the reticuloendothelial system (RES) and provide an effective enhanced permeability and retention (EPR) effect [63,64].”
BackgroundDynamic responsiveness of self‐assembling peptide‐based nano‐drug systems
Wang, Y., Zhan, J., Huang, J., Wang, X., Chen, Z., Yang, Z., & Li, J. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20220005 · Cited by 89
Xu, L., Xu, M., Sun, X., Feliu, N., Feng, L., Parak, W. J., & Liu, S. (2023) · ACS Nano · doi:10.1021/acsnano.2c07295 · Cited by 91
Arora, D., & Jaglan, S. (2016) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2016.06.003 · Cited by 92
Strategies for the enhanced intracellular delivery of nanomaterials
Azevedo, C., Macedo, M. H., & Sarmento, B. F. C. C. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.011 · Cited by 90
Blood TfR+ exosomes separated by a pH-responsive method deliver chemotherapeutics for tumor therapy
Yang, L., Han, D., Zhan, Q., Li, X., Shan, P., Hu, Y., Ding, H., Wang, Y., Zhang, L., Zhang, Y., et al. (2019) · Theranostics · doi:10.7150/thno.37220 · Cited by 90
“The negative zeta potential was beneficial to the drug delivery of TfR+ exosomes since nanoparticles with too high or too low surface potential were easily cleared by the immune system [31].”
BackgroundDNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy
Chi, Q., Yang, Z., Xu, K., Wang, C., & Liang, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01585 · Cited by 88
“Investigators sometimes choose to develop flexible, intelligent DNA nanodevices that overcome obstacles (Akita and Harashima, 2008; Blanco et al., 2015).”
BackgroundLi, Y., Lin, J., Cai, Z., Wang, P., Luo, Q., Yao, C., Zhang, Y., Hou, Z., Liu, J., & Liu, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.025 · Cited by 90
Ma, Y., Cai, F., Li, Y., Chen, J., Han, F., & Lin, W. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.05.002 · Cited by 89
“Cylindrical shape is the only shape affected by blood flow [72].”
BackgroundPET Tracing of Biodistribution for Orally Administered 64 Cu-Labeled Polystyrene in Mice
Im, C., Kim, H., Zaheer, J., Kim, J. Y., Lee, Y.-J., Kang, C. M., & Kim, J. S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.256982 · Cited by 91
“Generally, small nanoparticles penetrate capillary walls more easily than large nanoparticles, and positively charged nanoparticles are cleared more quickly by macrophages (32-34).”
BackgroundRuthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
Mahmud, K. M., Niloy, M. S., Shakil, M. S., & Islam, M. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081295 · Cited by 89
Yan, X., Pan, Q., Xin, H., Chen, Y., & Yuan, P. (2021) · Science Advances · doi:10.1126/sciadv.abj0624 · Cited by 88
“As opposed to light, small molecules can be ideally delivered in an organ-specific manner to reach the deep tissues from the site of administration, eliminating the critical issue of penetration depth that optical regulation suffers ( 15 ).”
Lymph node-targeting nanovaccines for cancer immunotherapy
Wang, Q., Wang, Z., Sun, X., Jiang, Q., Sun, B., He, Z., Zhang, S., Luo, C., & Sun, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.015 · Cited by 90
Gupta, P., Rai, N., Verma, A. K., Saikia, D., Singh, S. P., Kumar, R., Singh, S. K., Kumar, D., & Gautam, V. (2022) · ACS Omega · doi:10.1021/acsomega.2c05605 · Cited by 88
Non-viral gene therapy using multifunctional nanoparticles: Status, challenges, and opportunities
Lin, G., Li, L., Panwar, N., Wang, J., Tjin, S. C., Wang, X., & Yong, K. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.07.001 · Cited by 88
Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival
Bahmani, B., Uehara, M., Jiang, L., Ordikhani, F., Banouni, N., Ichimura, T., Solhjou, Z., Furtmüller, G. J., Brandacher, G., Álvarez, D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120923 · Cited by 88
Mashreghi, M., Zamani, P., Moosavian, S. A., & Jaafari, M. R. (2020) · Nanoscale Research Letters · doi:10.1186/s11671-020-03334-9 · Cited by 89
“It was shown that the increase in the size of nanoparticles to 150 nm enhance the liver, lung and spleen accumulation of nanoparticles [47].”
Backgroundα-Amino acid N-carboxyanhydride (NCA)-derived synthetic polypeptides for nucleic acids delivery
Liu, Y., & Yin, L. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.007 · Cited by 87
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121312 · Cited by 89
Nguyen, D. D., Yao, C., Lue, S. J., Yang, C.-J., Su, Y., Huang, C., & Lai, J. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.138620 · Cited by 87
Afterglow bio-applications by utilizing triplet excited states of organic materials
Fan, Y., Li, Q., & Li, Z. (2023) · Science China Chemistry · doi:10.1007/s11426-023-1790-0 · Cited by 91
Nanoparticle-enhanced drug delivery systems: An up-to-date review
Chenxi, Z., Hemmat, A., Thi, N., & Afrand, M. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.126999 · Cited by 87
Block copolymer crystalsomes with an ultrathin shell to extend blood circulation time
Qi, H., Zhou, H., Tang, Q., Lee, J. Y., Fan, Z., Kim, S., Staub, M. C., Zhou, T., Mei, S., Han, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05396-x · Cited by 90
Tong, W. Y., Alnakhli, M., Bhardwaj, R., Apostolou, S., Sinha, S., Fraser, C. K., Kuchel, T. R., Kuss, B. J., & Voelcker, N. H. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0365-y · Cited by 86
“Additionally, nanoparticles at 100 nm range have generally proven to be long-lasting in the circulation [34].”
BackgroundLiu, H., Shi, X., Wu, D., Khshen, F. K., Deng, L., Dong, A., Wang, W., & Zhang, J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b01987 · Cited by 86
Xu, Y., Wu, H. C., Huang, J., Qian, W., Martinson, D. E., Ji, B., Li, Y., Wang, Y. A., Yang, L. P. H., & Mao, H. Z. (2020) · Theranostics · doi:10.7150/thno.39560 · Cited by 88
“Noticeably, most of the earlier studies investigated NPs with core sizes of 10-300 nm which are favorable for EPR-driven passive targeting [22-23].”
BackgroundLight-induced liposomes for cancer therapeutics
Chen, W., Goldys, E. M., & Deng, W. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101052 · Cited by 87
The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment
Alven, S., & Aderibigbe, B. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121212 · Cited by 86
Wang, T., Rong, F., Tang, Y., Li, M., Feng, T., Zhou, Q., Li, P., & Huang, W. (2021) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2021.101389 · Cited by 88
Friedl, J. D., Nele, V., Rosa, G. D., & Bernkop‐Schnürch, A. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202103347 · Cited by 92
Ying, K., Zhu, Y., Wan, J., Zhan, C., Wang, Y., Xie, B., Xu, P., Pan, H., & Wang, H. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.06.013 · Cited by 86
“However, systemically administered nanotherapies are likely to Peer review under responsibility of KeAi Communications Co., Ltd. be sequestered by the host mononuclear phagocyte system (MPS), resulting in suboptimal pharmacokinetics and insufficient intratumor drug accumulation [5,6].”
Self-therapeutic metal-based nanoparticles for treating inflammatory diseases
Han, R., Xiao, Y., Bai, Q., & Choi, C. H. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.009 · Cited by 87
Tumor microenvironment and immunotherapy for triple-negative breast cancer
Guo, Z., Zhu, Z., Lin, X., Wang, S., Wen, Y., Wang, L., Zhi, L., & Zhou, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00714-6 · Cited by 95
Oh, Y., Santhamoorthy, M., Manivasagan, P., Bharathiraja, S., & Oh, J. (2016) · Biochimie · doi:10.1016/j.biochi.2016.11.012 · Cited by 86
Gao, X., Zhang, J., Huang, Z., Zuo, T., Lu, Q., Wu, G., & Shen, Q. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b05119 · Cited by 86
Wu, D., Li, Y., Yang, J., Shen, J., Zhou, J., Hu, Q., Yu, G., Tang, G., & Chen, X. S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b16734 · Cited by 85
The Growing Development of DNA Nanostructures for Potential Healthcare‐Related Applications
Mathur, D., & Medintz, I. L. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801546 · Cited by 85
Park, S., Kim, H., Lim, S. C., Lim, K., Lee, E. S., Oh, K. T., Choi, H., & Youn, Y. S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.036 · Cited by 85
“AuNPs as the unit material for making AuNCs were synthesized to be 5 nm because small nano-particles are more easily fi ltered through the kidney and less toxic than large nanoparticles [19,39].”
Wang, S., Shao, J., Li, Z., Ren, Q., Yu, X., & Liu, S. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02127 · Cited by 86
Lozano, O., Lázaro‐Alfaro, A., Silva‐Platas, C., Oropeza‐Almazán, Y., Torres‐Quintanilla, A., Bernal‐Ramírez, J., Alves‐Figueiredo, H., & García‐Rivas, G. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7683051 · Cited by 86
“the smaller NP size, with respect to that of this study, allowing for a faster cell uptake [17], as well as with the inherent faster uptake kinetic of cancerous cells.”
BackgroundInfluentialLi, Y., Ayala‐Orozco, C., Rauta, P. R., & Krishnan, S. (2019) · Nanoscale · doi:10.1039/c9nr05371a · Cited by 84
Delan, W. K., Zakaria, M., Elsaadany, B. A., ElMeshad, A. N., Mamdouh, W., & Fares, A. R. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119038 · Cited by 85
PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery
Xue, L., Yan, Y., Kós, P., Chen, X., & Siegwart, D. J. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00790-9 · Cited by 86
Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma
Brachi, G., Ruiz-Ramírez, J., Dogra, P., Wang, Z., Vittorio Cristini, C., Ciardelli, G., Rostomily, R., Mauro Ferrari, B., Mikheev, A. M., Blanco, E., et al. (2020) · Nanoscale · doi:10.1039/d0nr05053a · Cited by 89
Self-citationNanotechnology for pain management: Current and future therapeutic interventions
Bhansali, D., Teng, S. L., Lee, C. S., Schmidt, B. L., Bunnett, N. W., & Leong, K. W. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101223 · Cited by 85
“surface charge, and cargo dose that can be optimized to prolong drug circulation and to target specific tissues or subcellular organelles [52,53].”
BackgroundLure-and-kill macrophage nanoparticles alleviate the severity of experimental acute pancreatitis
Zhang, Q., Zhou, J., Zhou, J., Fang, R. H., Gao, W., & Zhang, L. (2021) · Nature Communications · doi:10.1038/s41467-021-24447-4 · Cited by 85
Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics
Ang, M. J. Y., Chan, S. Y., Goh, Y. Y., Luo, Z., Lau, J. W., & Liu, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113907 · Cited by 87
Mechano‐Responsive Leapfrog Micelles Enable Interactive Apoptotic and Ferroptotic Cancer Therapy
Li, Y., Qin, Y., Shang, Y., Li, Y., Liu, F., Luo, J., Zhu, J., Guo, X., Wang, Z., & Zhao, Y. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202112000 · Cited by 84
Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum
Tiambeng, T. N., Roberts, D. S., Brown, K. A., Zhu, Y., Chen, B., Wu, Z., Mitchell, S. D., Guardado-Alvarez, T. M., Jin, S., & Ge, Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17643-1 · Cited by 76
“Roman numerals correspond to N-terminally acetylated cTnI proteoforms following Met exclusion: (i) ppcTnI[1-207]; (ii) cTnI; (iii) pcTnI; (iv) ppcTnI; (v) cTnI[1-205]; (vi) pcTnI[1-205]; (vii) cTnI[1-206]; (viii) pcTnI[1-206].”
Background
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
